Volume 18, Issue 5 , Pages 384-388, September 2009
Apolipoprotein E, Alcohol Consumption, and Risk of Ischemic Stroke: The Framingham Heart Study Revisited
Background
Data on the association between alcohol consumption and ischemic stroke have been inconsistent. It is not known whether allele ɛ4 of the apolipoprotein E (apoE) gene modifies the alcohol-stroke association. We sought to examine whether ɛ4 allele of the apoE gene influences the association between alcohol consumption and ischemic stroke or high-density lipoprotein (HDL) cholesterol.
Methods
We examined a cohort of 7676 person-observations of the Framingham Heart Study. Incident stroke was ascertained by standardized methods. We used Cox proportional hazard model to estimate hazard ratios of ischemic stroke.
Results
The average age at baseline was 63 years and 55% of the participants were women. During a mean follow-up of 7.4 years, 222 new cases of ischemic stroke occurred (56 embolic and 166 atherothrombotic events). Comparing current drinkers with nondrinkers, multivariable adjusted hazard ratio (95% confidence interval) for ischemic stroke was 0.50 (0.24-1.07) in the absence of ɛ4 allele and 0.70 (0.24-2.05) in the presence of ɛ4 allele (P for interaction = .64) for those younger than 65 years. Similarly, we did not observe a statistically significant interaction between ɛ4 allele and alcohol consumption on the risk of stroke among people aged 65 years and older (P for interaction = .17). Alcohol consumption was positively associated with HDL cholesterol independent of ɛ4 allele and age.
Conclusions
Our data do not provide evidence for an interaction between ɛ4 allele and alcohol consumption on the risk of ischemic stroke in this population. Furthermore, apoE polymorphism did not influence the alcohol-HDL relation.
Key Words: Alcohol drinking, ischemic stroke, apolipoprotein E gene, lipids
To access this article, please choose from the options below
Supported by the National Heart, Lung, and Blood Institute's (NHLBI) Framingham Heart Study contract No. N01-HC-25195, National Institute of Health, Bethesda, MD, and a grant from the National Institute of Neurological Disorders and Stroke (5RO1-NS 017950, Philip A. Wolf, MD, Principal Investigator). Dr. Djoussé was partially supported by K01 HL-70444 from the NHLBI.
PII: S1052-3057(09)00023-8
doi:10.1016/j.jstrokecerebrovasdis.2009.01.008
© 2009 National Stroke Association. Published by Elsevier Inc. All rights reserved.
Volume 18, Issue 5 , Pages 384-388, September 2009
